PhorMed, Inc.

—Pipeline
Pipeline
Clinical Pipeline for RCL/929
Indication
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
Clinical Pipeline for RCL/929
Acute Myeloid Leukemia
RLC/929-1-C01
Hodgkin's Lymphoma
RLC/929-1-C02
Pulmonary Inflammation/ARDS
*RLC/929-3-I01
Parkinson's Disease
*RLC/929-2-N02
Stroke
RLC/929-2-N01
Coming Soon
*RLC/929-4-H02

* Clinical profile for RCL/929: Phase I Clinical Safety Studies completed. Not required to repeated Phase I when developing new indications using RCL/929 but an abbreviated Phase IB might be required, a Phase I/II Study.

Clinical Pipeline
  • Phase II Trials:
    • Acute Myeloid Leukemia (AML)
    • Hodgkin’s Lymphoma (HL)
    • Acute Respiratory Distress Syndrome (ARDS)
  • Preclinical Stage:
    • Parkinson’s Disease (PD)